Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

Topline results from the Chinese portion of the trial for the antibody-drug conjugate (ADC) TIVDAK support the company’s ...

Zai Lab (ZLAB) stock rose after positive trial data for its cervical cancer drug Tivdak and its plans to seek marketing ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Quantum Dot Corporation's (QDC) new western blot detection kits harness the high brightness, extreme stability and multiple colors of the Qdot Secondary Antibody Conjugates to quantitatively ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.